Next Article in Journal
Randomized Controlled Trial of DHA Supplementation during Pregnancy: Child Adiposity Outcomes
Next Article in Special Issue
Toxoplasma Gondii Moderates the Association between Multiple Folate-Cycle Factors and Cognitive Function in U.S. Adults
Previous Article in Journal
Vitamin C Depletion and All-Cause Mortality in Renal Transplant Recipients
Previous Article in Special Issue
Preoperative Nutritional Conditioning of Crohn’s Patients—Systematic Review of Current Evidence and Practice
Open AccessArticle

The Evolving Interplay among Abundant Adipokines in Patients with Hepatitis C during Viral Clearance

Liver Research Center, Division of Hepatology, Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Taoyuan 33305, Taiwan
Department of Medicine, College of Medicine, Chang Gung University, Taoyuan 33305, Taiwan
Author to whom correspondence should be addressed.
Nutrients 2017, 9(6), 570;
Received: 4 April 2017 / Revised: 4 May 2017 / Accepted: 31 May 2017 / Published: 2 June 2017
(This article belongs to the Special Issue Nutrients, Infectious and Inflammatory Diseases)
How hepatatitis C virus (HCV) infection affects the interplay among abundant adipokines in the host remains unclear. A prospective study was conducted with 450 consecutive genotype 1 (G1) and G2 HCV patients who completed a course of anti-HCV therapy and underwent pre-therapy and 24-week post-therapy surveys to assess various profiles and levels of abundant adipokines, including leptin, adiponectin, and plasminogen activator inhibitor-1 (PAI-1). Before anti-HCV therapy, multivariate analyses showed gender to be associated with leptin and adiponectin levels, and BMI with leptin and PAI-1 levels. Among patients with a sustained virological response (SVR, n = 372), associations at 24 weeks post-therapy were as follows: gender and BMI with all adipokine levels; hepatic steatosis and aspartate aminotransferase to platelet ratio index with adiponectin levels; and HOMA-IR and HCV genotype with PAI-1 levels. Paired t-tests revealed increased post-therapeutic PAI-1 levels in G1 SVR patients and decreased adiponectin levels in all SVR patients compared to pre-therapeutic levels. HCV infection may obscure associations between abundant adipokines and metabolic/hepatic profiles. In SVR patients, a higher hierarchical status of PAI-1 versus adiponectin in affecting glucose metabolism was noted at 24 weeks post-therapy. Such genotype-non-specific adiponectin decreases and G1-specific PAI-1 increases warrant careful follow-up of HCV patients after SVR according to viral genotype. View Full-Text
Keywords: HCV; SVR; leptin; adiponectin; PAI-1; HOMA-IR HCV; SVR; leptin; adiponectin; PAI-1; HOMA-IR
Show Figures

Figure 1

MDPI and ACS Style

Chang, M.-L.; Chen, T.-H.; Hsu, C.-M.; Lin, C.-H.; Lin, C.-Y.; Kuo, C.-J.; Huang, S.-W.; Chen, C.-W.; Cheng, H.-T.; Yeh, C.-T.; Chiu, C.-T. The Evolving Interplay among Abundant Adipokines in Patients with Hepatitis C during Viral Clearance. Nutrients 2017, 9, 570.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop